Halozyme Therapeutics Management
Management criteria checks 2/4
Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 10.83 years. total yearly compensation is $11.82M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $36.52M. The average tenure of the management team and the board of directors is 2.8 years and 10.8 years respectively.
Key information
Helen Torley
Chief executive officer
US$11.8m
Total compensation
| CEO salary percentage | 7.8% |
| CEO tenure | 10.8yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.8yrs |
| Board average tenure | 10.8yrs |
Recent management updates
Recent updates
Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 05Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29
Halozyme Therapeutics: Behind The Pullback
Oct 22Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$392m |
| Jun 30 2024 | n/a | n/a | US$337m |
| Mar 31 2024 | n/a | n/a | US$319m |
| Dec 31 2023 | US$12m | US$920k | US$282m |
| Sep 30 2023 | n/a | n/a | US$254m |
| Jun 30 2023 | n/a | n/a | US$234m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$10m | US$872k | US$202m |
| Sep 30 2022 | n/a | n/a | US$211m |
| Jun 30 2022 | n/a | n/a | US$366m |
| Mar 31 2022 | n/a | n/a | US$435m |
| Dec 31 2021 | US$7m | US$830k | US$403m |
| Sep 30 2021 | n/a | n/a | US$409m |
| Jun 30 2021 | n/a | n/a | US$229m |
| Mar 31 2021 | n/a | n/a | US$163m |
| Dec 31 2020 | US$7m | US$791k | US$129m |
| Sep 30 2020 | n/a | n/a | US$22m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$6m | US$761k | -US$72m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$43m |
| Mar 31 2019 | n/a | n/a | -US$51m |
| Dec 31 2018 | US$6m | US$725k | -US$80m |
| Sep 30 2018 | n/a | n/a | US$46m |
| Jun 30 2018 | n/a | n/a | US$76m |
| Mar 31 2018 | n/a | n/a | US$68m |
| Dec 31 2017 | US$5m | US$671k | US$63m |
Compensation vs Market: Helen's total compensation ($USD11.82M) is above average for companies of similar size in the US market ($USD7.83M).
Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.
CEO
Helen Torley (61 yo)
10.8yrs
Tenure
US$11,820,858
Compensation
Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$11.82m | 0.53% $ 36.5m | |
| Senior VP & CFO | 2.8yrs | US$3.85m | 0.012% $ 835.5k | |
| Senior VP & CTO | no data | US$3.24m | 0.14% $ 9.4m | |
| Senior VP & Chief Legal Officer | 2.8yrs | US$3.61m | 0.0092% $ 630.2k | |
| Chief Operations Officer | 1.1yrs | no data | no data | |
| Head of Investor Relations & Corporate Communications | 2.8yrs | no data | no data | |
| Chief Human Resources Officer | 4.8yrs | no data | no data | |
| Chief Commercial Officer | 1.5yrs | no data | no data | |
| Chief Business Officer | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
2.8yrs
Average Tenure
60yo
Average Age
Experienced Management: HALO's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.8yrs | US$11.82m | 0.53% $ 36.5m | |
| Independent Director | 18.3yrs | US$460.02k | 0.15% $ 10.1m | |
| Independent Chair of the Board | 9.3yrs | US$555.02k | 0.037% $ 2.5m | |
| Member of the Scientific Advisory Board | 20.3yrs | no data | no data | |
| Independent Director | 1.8yrs | US$528.15k | no data | |
| Member of the Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | 10.8yrs | US$68.17k | no data | |
| Member of Scientific Advisory Board | 20.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 19.3yrs | no data | no data | |
| Independent Director | 11.7yrs | US$471.83k | 0.039% $ 2.7m | |
| Independent Director | 2.7yrs | US$455.02k | 0.011% $ 770.3k | |
| Independent Director | 6.2yrs | US$470.02k | 0.032% $ 2.2m |
10.8yrs
Average Tenure
66yo
Average Age
Experienced Board: HALO's board of directors are seasoned and experienced ( 10.8 years average tenure).